Edition:
India

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

25.10USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$25.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
65,638
52-wk High
$40.56
52-wk Low
$19.85

Select another date:

Fri, Dec 8 2017

BRIEF-Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko

* REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK)

BRIEF-Reata Pharmaceuticals files for offering of up to $50.0 million of shares of Class A common stock‍​

* Files for offering of up to $50.0 million of shares of Class A common stock‍​ - SEC filing Source text : (http://bit.ly/2AG2XNP) Further company coverage:

BRIEF-Reata Pharmaceuticals Q3 loss per share $0.50

* Reata Pharmaceuticals Inc announces third quarter 2017 financial and operating results

BRIEF-Reata Pharmaceuticals enters first amendment to loan and security agreement​

* Reata Pharmaceuticals says ‍on November 3, co entered into a first amendment to loan and security agreement​ - SEC filing

BRIEF-Reata provides update on Bardoxolone Methyl from American Society of Nephrology Kidney Week Meeting

* Reata provides update on bardoxolone methyl from the american society of nephrology kidney week meeting

BRIEF-Reata Pharmaceuticals says top-line data to be available in 2019 for omaveloxolone​

* Reata Pharmaceuticals Inc - ‍announces first patient enrolled in Part 2 of Moxie study of omaveloxolone for treatment of Friedreich's Ataxia​

BRIEF-Reata Pharma receives orphan drug designation for Omaveloxolone

* Reata Pharmaceuticals Inc receives orphan drug designation for Omaveloxolone for the treatment of malignant melanoma

BRIEF-Reata Pharmaceuticals Q2 loss per share $0.52

* Reata pharmaceuticals Inc announces second quarter 2017 financial and operating results

BRIEF-Reata announces first patient enrolled in Phase 3 Cardinal trial of Bardoxolone Methyl in the treatment of chronic kidney disease due to Alport Syndrome

* Reata announces first patient enrolled in phase 3 cardinal trial of Bardoxolone Methyl in the treatment of chronic kidney disease due to Alport Syndrome Source text for Eikon: Further company coverage:

BRIEF-William Rose reports 15.4 percent stake in Reata Pharmaceuticals Inc as on Aug 1

* William Rose reports 15.4 percent stake in Reata Pharmaceuticals Inc as on Aug 1 - SEC filing‍​

Select another date: